BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24021190)

  • 1. Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir.
    Field HJ; Huang ML; Lay EM; Mickleburgh I; Zimmermann H; Birkmann A
    Antiviral Res; 2013 Nov; 100(2):297-9. PubMed ID: 24021190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
    Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
    J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of spontaneous helicase-primase inhibitor (BAY 57-1293) drug-resistant variants in certain laboratory isolates of HSV-1.
    Biswas S; Swift M; Field HJ
    Antivir Chem Chemother; 2007; 18(1):13-23. PubMed ID: 17354648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics-pharmacodynamics of the helicase-primase inhibitor pritelivir following treatment of wild-type or pritelivir-resistant virus infection in a murine herpes simplex virus 1 infection model.
    Biswas S; Sukla S; Goldner T; Field HJ; Kropeit D; Paulsen D; Welbers A; Ruebsamen-Schaeff H; Zimmermann H; Birkmann A
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3843-52. PubMed ID: 24752278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir).
    Chono K; Katsumata K; Kontani T; Shiraki K; Suzuki H
    Biochem Pharmacol; 2012 Aug; 84(4):459-67. PubMed ID: 22687623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1.
    Biswas S; Smith C; Field HJ
    J Antimicrob Chemother; 2007 Aug; 60(2):274-9. PubMed ID: 17550887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase.
    Liuzzi M; Kibler P; Bousquet C; Harji F; Bolger G; Garneau M; Lapeyre N; McCollum RS; Faucher AM; Simoneau B; Cordingley MG
    Antiviral Res; 2004 Dec; 64(3):161-70. PubMed ID: 15550269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target.
    Biswas S; Kleymann G; Swift M; Tiley LS; Lyall J; Aguirre-Hernández J; Field HJ
    J Antimicrob Chemother; 2008 May; 61(5):1044-7. PubMed ID: 18299638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.
    Duan J; Liuzzi M; Paris W; Liard F; Browne A; Dansereau N; Simoneau B; Faucher AM; Cordingley MG
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1798-804. PubMed ID: 12760851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease.
    Crute JJ; Grygon CA; Hargrave KD; Simoneau B; Faucher AM; Bolger G; Kibler P; Liuzzi M; Cordingley MG
    Nat Med; 2002 Apr; 8(4):386-91. PubMed ID: 11927945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicase-primase inhibitor pritelivir for HSV-2 infection.
    Wald A; Corey L; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Kriesel J; Fife K; Galitz L; Stoelben S; Huang ML; Selke S; Stobernack HP; Ruebsamen-Schaeff H; Birkmann A
    N Engl J Med; 2014 Jan; 370(3):201-10. PubMed ID: 24428466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High conservation of herpes simplex virus UL5/UL52 helicase-primase complex in the era of new antiviral therapies.
    Collot M; Rouard C; Brunet C; Agut H; Boutolleau D; Burrel S
    Antiviral Res; 2016 Apr; 128():1-6. PubMed ID: 26826441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis.
    Quenelle DC; Birkmann A; Goldner T; Pfaff T; Zimmermann H; Bonsmann S; Collins DJ; Rice TL; Prichard MN
    Antiviral Res; 2018 Jan; 149():1-6. PubMed ID: 29113740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome.
    Ziyaeyan M; Alborzi A; Japoni A; Kadivar M; Davarpanah MA; Pourabbas B; Abassian A
    Int J Dermatol; 2007 Dec; 46(12):1263-6. PubMed ID: 18173520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
    Biswas S; Tiley LS; Zimmermann H; Birkmann A; Field HJ
    Antiviral Res; 2008 Oct; 80(1):81-5. PubMed ID: 18539344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy.
    Edlefsen PT; Birkmann A; Huang ML; Magaret CA; Kee JJ; Diem K; Goldner T; Timmler B; Stoelben S; Ruebsamen-Schaeff H; Zimmermann H; Warren T; Wald A; Corey L
    J Infect Dis; 2016 Jul; 214(2):258-64. PubMed ID: 27056950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The helicase-primase inhibitor BAY 57-1293 reduces the Alzheimer's disease-related molecules induced by herpes simplex virus type 1.
    Wozniak MA; Frost AL; Itzhaki RF
    Antiviral Res; 2013 Sep; 99(3):401-4. PubMed ID: 23867133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex.
    Spector FC; Liang L; Giordano H; Sivaraja M; Peterson MG
    J Virol; 1998 Sep; 72(9):6979-87. PubMed ID: 9696789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytopathic effect inhibition assay for determining the in-vitro susceptibility of herpes simplex virus to antiviral agents.
    Cotarelo M; Catalán P; Sánchez-Carrillo C; Menasalvas A; Cercenado E; Tenorio A; Bouza E
    J Antimicrob Chemother; 1999 Nov; 44(5):705-8. PubMed ID: 10552991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture.
    Biswas S; Jennens L; Field HJ
    Arch Virol; 2007; 152(8):1489-500. PubMed ID: 17404685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.